Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption (Nursma-CIRC-HG)

11 de mayo de 2026 actualizado por: Cuneyt Asim Aral, Inonu University

Investigation of Circadian Clock Gene/Proteins in Individuals With and Without Disrupted Circadian Rhythm: A Prospective Cross-Sectional Clinical Study

This prospective cross-sectional clinical study aims to investigate the relationship between circadian rhythm disruption and periodontal inflammation by evaluating circadian clock protein levels, inflammatory (IL-1beta) and anti-inflammatory (IL-10) cytokine levels in gingival crevicular fluid (GCF) of individuals with and without circadian rhythm disruption.

Participants aged 20-50 years will be classified into four groups based on their circadian rhythm status (disrupted/normal) and gingival health status (gingivitis/healthy). Clinical periodontal parameters including plaque index, gingival index, bleeding on probing, and probing depth will be assessed. Circadian rhythm status will be determined using validated questionnaires (Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire). Night-shift workers will represent the circadian rhythm disruption group.

GCF samples will be analyzed for circadian clock proteins (BMAL-1, CLOCK, PER-1, PER-2, PER-3, CRY-1, CRY-2, REV-ERB-beta, MTNR1B) and cytokines (IL-1beta, IL-10) using ELISA. Serum cortisol and melatonin levels will be measured for biochemical verification of circadian rhythm status.

Gingivitis groups will receive standard periodontal treatment and be re-evaluated at 2 weeks post-treatment. A total of 116 participants (29 per group) are planned for enrollment.

Descripción general del estudio

Descripción detallada

Gingival tissue plays a critical role in maintaining oral health as a fundamental component of periodontal tissues. Recent evidence suggests that circadian rhythm mechanisms, beyond microbial factors, may significantly influence periodontal disease pathogenesis through modulation of host immune responses.

The circadian rhythm is an endogenous mechanism regulating biological processes in approximately 24-hour physiological and behavioral cycles, controlled centrally by the suprachiasmatic nucleus in the hypothalamus. At the molecular level, core clock genes (CLOCK, BMAL1, PER1-3, CRY1-2) operate through the Transcription-Translation Feedback Loop (TTFL). CLOCK and BMAL1 proteins form heterodimers in the cell nucleus, bind to E-box regions on DNA, and initiate transcription of PER and CRY genes. Subsequently, PER and CRY proteins synthesized in the cytoplasm return to the nucleus and inhibit the CLOCK-BMAL1 complex, creating approximately 24-hour rhythmic gene expression cycles. Regulatory nuclear receptors such as REV-ERBa and ROR also contribute to the fine-tuning of this mechanism.

Recent studies have demonstrated the presence of functional peripheral clock mechanisms in periodontal tissues. CLOCK, BMAL1, PER1-3, and CRY1-2 gene expression has been identified in gingival fibroblasts and periodontal ligament fibroblasts. Experimental studies have shown that circadian rhythm disruption can increase inflammatory processes, enhance macrophage activation, elevate inflammatory cytokine production, and accelerate alveolar bone loss in periodontitis models.

Despite these findings, human studies evaluating the relationship between inflammatory cytokines and circadian rhythm proteins in gingival crevicular fluid (GCF) remain limited. This study addresses this gap by evaluating gingival health status using clinical periodontal parameters in individuals with and without circadian rhythm disruption.

Study Design:

Participants will be classified into four groups based on circadian rhythm status and periodontal health:

  • Group 1: Normal circadian rhythm / Periodontally healthy (control)
  • Group 2: Normal circadian rhythm / Gingivitis
  • Group 3: Circadian rhythm disruption / Periodontally healthy
  • Group 4: Circadian rhythm disruption / Gingivitis
  • Group 5: Group 2 at 2 weeks post-periodontal treatment
  • Group 6: Group 4 at 2 weeks post-periodontal treatment

Time Points:

T0 (Baseline): Clinical periodontal examination, GCF, saliva, and serum sampling in all groups.

T1 (Day 14): Re-evaluation of clinical parameters and biological sampling in gingivitis groups after standard periodontal treatment.

Clinical Periodontal Assessment:

All periodontal measurements will be performed by a single examiner using a standard periodontal probe at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual). Parameters include plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), and clinical attachment level (CAL).

GCF Sampling:

GCF samples will be collected using sterile Periopaper strips placed in the gingival sulcus for 30 seconds after supragingival plaque removal and isolation. GCF volumes will be quantified using a Periotron device. Samples contaminated with blood will be excluded.

Saliva Sampling:

Unstimulated saliva samples will be collected as an alternative biological material if circadian rhythm proteins cannot be detected at sufficient levels in GCF.

Serum Sampling:

Venous blood samples will be collected from the antecubital vein for biochemical evaluation of circadian rhythm status through cortisol and melatonin level analysis.

All biological samples will be collected during standardized morning hours (09:00-11:00) to minimize diurnal variation in biomarker levels.

Laboratory Analysis:

GCF samples will be analyzed using ELISA for circadian rhythm-related proteins (MTNR1B, BMAL-1, CLOCK, PER-1, PER-2, PER-3, CRY-1, CRY-2, REV-ERB-beta) and inflammatory biomarkers (IL-1beta and IL-10).

Statistical Analysis:

Data will be analyzed using SPSS. Normality will be assessed by Shapiro-Wilk test. Comparisons among independent groups will use one-way ANOVA or Kruskal-Wallis test, with Tukey or Dunn post-hoc tests. Pre- and post-treatment comparisons will use paired t-test or Wilcoxon signed-rank test. Correlations will be assessed by Pearson or Spearman analysis. Multivariate regression models will control for age, sex, BMI, and waist circumference as covariates. Significance level: p < 0.05.

This study was approved by the Inonu University Health Sciences Scientific Research Ethics Committee and will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all participants.

Tipo de estudio

De observación

Inscripción (Estimado)

116

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Cüneyt A Aral, Chair, Professor Dr, DDS, PhD
  • Número de teléfono: +905424577657
  • Correo electrónico: cuneytasimaral@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Kübra Aral, Assoc. Professor, DDS, PhD
  • Número de teléfono: +905330578801
  • Correo electrónico: drkubraaral@gmail.com

Ubicaciones de estudio

    • Malatya
      • Malatya, Malatya, Turquía (Türkiye), 44210
        • Inönü University Faculty of Dentistry, Department of Periodontology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Método de muestreo

Muestra no probabilística

Población de estudio

Systemically healthy volunteers aged 20-50 years presenting to Inonu University Faculty of Dentistry, Department of Periodontology. The study population includes individuals with normal circadian rhythm and night-shift workers with circadian rhythm disruption. Participants are classified as periodontally healthy or with gingivitis based on clinical periodontal examination. Circadian rhythm status is verified using the Morningness-Eveningness Questionnaire (MEQ) and Munich Chronotype Questionnaire (MCTQ).

Descripción

Inclusion Criteria:

  • Aged between 20 and 50 years
  • Systemically healthy
  • Diagnosed as periodontally healthy or with gingivitis based on clinical periodontal examination
  • Having at least 20 natural teeth in the oral cavity
  • Willing to provide written informed consent
  • Agreeing to participate in circadian rhythm assessment and completing the Morningness-Eveningness Questionnaire (MEQ) and Munich Chronotype Questionnaire (MCTQ)
  • Sleep duration of 6-9 hours per day
  • For periodontally healthy: PD <=3 mm, BOP <10%, CAL=0, no radiographic bone loss
  • For gingivitis: PD <=3 mm, 10%<=BOP<=30%, CAL=0, no radiographic bone loss
  • For circadian rhythm disruption group: being a night-shift worker

Exclusion Criteria:

  • Use of antioxidant or melatonin supplements
  • Presence of any systemic disease
  • Use of antibiotics, anti-inflammatory drugs, or immunosuppressants within the past 3 months
  • Having received periodontal treatment within the past 6 months
  • Pregnancy or lactation
  • Use of tobacco or tobacco products
  • Presence of acute oral infection, abscess, or advanced periodontal disease
  • Currently undergoing orthodontic treatment or having fixed orthodontic appliances
  • Inability to comply with study procedures or refusal to provide informed consent
  • Self-reported sleep duration less than 6 hours or greater than 9 hours per day

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Normal Circadian / Periodontally Healthy
Individuals with normal circadian rhythm and periodontal health (control group). Inclusion: PD <=3 mm, BOP <10%, CAL=0, no radiographic bone loss. n=29
Normal Circadian / Gingivitis
Individuals with normal circadian rhythm and gingivitis. Inclusion: PD <=3 mm, 10%<=BOP<=30%, CAL=0, no radiographic bone loss. These participants will receive standard periodontal treatment and be re-evaluated at 14 days post-treatment. n=29
Standard periodontal treatment including detailed oral hygiene instruction and professional dental surface cleaning (scaling and polishing). Applied to gingivitis groups (Group 2 and Group 4) at baseline, with clinical and biochemical re-evaluation at 14 days post-treatment.
Disrupted Circadian / Periodontally Healthy
Night-shift workers with circadian rhythm disruption and periodontal health. Circadian rhythm status verified by MEQ and MCTQ questionnaires. Inclusion: PD <=3 mm, BOP <10%, CAL=0, no radiographic bone loss. n=29
Disrupted Circadian / Gingivitis
Night-shift workers with circadian rhythm disruption and gingivitis. Circadian rhythm status verified by MEQ and MCTQ questionnaires. Inclusion: PD <=3 mm, 10%<=BOP<=30%, CAL=0, no radiographic bone loss. These participants will receive standard periodontal treatment and be re-evaluated at 14 days post-treatment. n=29
Standard periodontal treatment including detailed oral hygiene instruction and professional dental surface cleaning (scaling and polishing). Applied to gingivitis groups (Group 2 and Group 4) at baseline, with clinical and biochemical re-evaluation at 14 days post-treatment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
GCF Circadian Rhythm Protein Levels
Periodo de tiempo: Baseline (T0) and 14 days post-treatment (T1) for gingivitis groups
Concentrations of circadian clock proteins (BMAL-1, CLOCK, PER-1, PER-2, PER-3, CRY-1, CRY-2, REV-ERB-beta, MTNR1B) measured in gingival crevicular fluid (GCF) using ELISA. GCF collected with Periopaper strips placed in the gingival sulcus for 30 seconds. Volumes quantified using a Periotron device.
Baseline (T0) and 14 days post-treatment (T1) for gingivitis groups
GCF Inflammatory Cytokine Levels
Periodo de tiempo: Baseline (T0) and 14 days post-treatment (T1) for gingivitis groups
Interleukin-1 beta (IL-1beta, pro-inflammatory) and Interleukin-10 (IL-10, anti-inflammatory) cytokine concentrations in gingival crevicular fluid measured by ELISA.
Baseline (T0) and 14 days post-treatment (T1) for gingivitis groups

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Cüneyt A Aral, Professor, DDS, PhD, Inonu University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de agosto de 2026

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de mayo de 2026

Publicado por primera vez (Actual)

18 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir